مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

123
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

49
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Non-Requirement to Blood Transfusion in a Patient With Myelodysplastic Syndrome Following the Oral Administration of β-D-Mannuronic Acid: A Case Report

Pages

  57-60

Keywords

D-mannuronic acid (M2000) 
Myelodysplastic syndrome (MDS) 

Abstract

 Myelodysplastic Syndromes (MDSs) is a heterogeneous group of hematologic neoplasms that causes cytopenia and dysplasia in one or more major bone marrow cell lines. The patients with this syndrome develop clinical complications associated with progressive bone marrow destruction leading to an increased risk for acute myelogenous leukemia. In the treatment of this syndrome, repeated infusion of Red Blood Cells (RBCs) may lead to iron overload, which is associated with a reduction in the survival rate of patients. In this paper, we report a case with MDS whose risk of dependence on blood Transfusion was interstitial and received 4 units of packed RBCs once every 4 weeks. He had enrolled in our current clinical trial of β-D-mannuronic acid (M2000) in Iranian MDS patients. This 68-year-old man was treated with M2000, 500-mg capsule every 12 hours for 3 months. After 3 months of treatment, he experienced a non-requirement to blood Transfusion following a hemoglobin increase of more than 2. 5 g/dL in his blood sample. Moreover, the patient’ s life quality was improved. This case report showed that M2000 drug might be an effective treatment for Transfusiondependent MDS patients (Clinical trial identifier; IRCT20130622013739N11).

Cites

  • No record.

    • References

    Cite

    APA: Copy

    Ghaderi, Afshin, Safaee Nodehi, Sayyed Reza, Bakhtiari, Tahereh, & MIRSHAFIEY, ABBAS. (2019). Non-Requirement to Blood Transfusion in a Patient With Myelodysplastic Syndrome Following the Oral Administration of β-D-Mannuronic Acid: A Case Report. CASE REPORTS IN CLINICAL PRACTICE, 4(2), 57-60. SID. https://sid.ir/paper/758380/en

    Vancouver: Copy

    Ghaderi Afshin, Safaee Nodehi Sayyed Reza, Bakhtiari Tahereh, MIRSHAFIEY ABBAS. Non-Requirement to Blood Transfusion in a Patient With Myelodysplastic Syndrome Following the Oral Administration of β-D-Mannuronic Acid: A Case Report. CASE REPORTS IN CLINICAL PRACTICE[Internet]. 2019;4(2):57-60. Available from: https://sid.ir/paper/758380/en

    IEEE: Copy

    Afshin Ghaderi, Sayyed Reza Safaee Nodehi, Tahereh Bakhtiari, and ABBAS MIRSHAFIEY, “Non-Requirement to Blood Transfusion in a Patient With Myelodysplastic Syndrome Following the Oral Administration of β-D-Mannuronic Acid: A Case Report,” CASE REPORTS IN CLINICAL PRACTICE, vol. 4, no. 2, pp. 57–60, 2019, [Online]. Available: https://sid.ir/paper/758380/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button